ANIP Q3 2021 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$52M-1.7% YoY

Gross Profit

$28M53.1% margin

Operating Income

-$4M-6.8% margin

Net Income

-$4M-8.5% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$470M

Total Liabilities

$279M

Stockholders' Equity

$191M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$53M	-1.7%
Gross Profit	$28M	$33M	-15.9%
Operating Income	-$4M	$3M	-227.1%
Net Income	-$4M	$434,000	-1124.7%

Revenue Segments

Sales Of Generic Pharmaceutical Products

$35M67%

Sales Of Branded Pharmaceutical Products

$14M27%

Sales Of Contract Manufactured Products

$3M6%

Other Revenues

$149,0000%

Product Development Services

$77,0000%

Geographic Segments

U

$51M98%

C

$961,0002%